Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15

Barclays analyst Etzer Darout has maintained an Overweight rating on Iovance Biotherapeutics (NASDAQ: IOVA) and raised the price target from $13 to $15. This adjustment reflects a positive outlook for the company in the market.